Assembly Biosciences (ASMB) Total Non-Current Liabilities (2014 - 2018)

Assembly Biosciences' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $38.9 million for Q4 2018.

• On a quarterly basis, Total Non-Current Liabilities fell 8.84% year-over-year to $38.9 million in Q4 2018; TTM through Dec 2018 was $38.9 million, a 8.84% decrease from a year earlier, with the FY2018 full-year figure at $38.9 million, down 8.84% from the prior year.
• Total Non-Current Liabilities held at $38.9 million in Q4 2018 per ASMB's latest filing, from $38.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $55.4 million in Q1 2017 and bottomed at $11.1 million in Q4 2016.
• The 5-year median for Total Non-Current Liabilities is $25.3 million (2014), against an average of $28.6 million.
• Across the five-year window, Total Non-Current Liabilities soared 377.93% in 2017 and retreated 26.49% in 2018, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $11.6 million in 2014, then changed by 0.0% to $11.6 million in 2015, then dropped by 4.14% to $11.1 million in 2016, then surged by 283.93% to $42.7 million in 2017, then declined by 8.84% to $38.9 million in 2018.
• Per Business Quant, the three latest ASMB Total Non-Current Liabilities figures stand at $38.9 million (Q4 2018), $38.9 million (Q3 2018), and $40.2 million (Q2 2018).